We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Investigator-initiated trials of targeted oncology agents: why independent research is at risk?
- Authors
Bergmann, L; Berns, B; Dalgleish, A G; von Euler, M; Hecht, T T; Lappin, G L; Reed, N; Palmeri, S; Smyth, J; Embacher-Aichorn, S; Zwierzina, H; Biotherapy Development Association
- Abstract
Drug development traditionally has relied upon the complementary contributions of clinicians and scientists at academic institutions and at pharmaceutical companies. Greater regulatory burdens, increased bureaucratic requirements, restricted reimbursement, and spiralling research and development costs are exerting pressure on the drug development pipeline. The result is a de-emphasis of exploratory research, particularly independent academic research, despite its proven value in identifying new drug targets and developing innovative cancer therapies.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Vol 21, Issue 8, p1573
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdq018